IBDEI1RY ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,31330,1,4,0)
 ;;=4^M48.33
 ;;^UTILITY(U,$J,358.3,31330,2)
 ;;=^5012117
 ;;^UTILITY(U,$J,358.3,31331,0)
 ;;=M48.34^^180^1951^75
 ;;^UTILITY(U,$J,358.3,31331,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31331,1,3,0)
 ;;=3^Traumatic spondylopathy, thoracic region
 ;;^UTILITY(U,$J,358.3,31331,1,4,0)
 ;;=4^M48.34
 ;;^UTILITY(U,$J,358.3,31331,2)
 ;;=^5012118
 ;;^UTILITY(U,$J,358.3,31332,0)
 ;;=R47.01^^180^1952^1
 ;;^UTILITY(U,$J,358.3,31332,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31332,1,3,0)
 ;;=3^Aphasia
 ;;^UTILITY(U,$J,358.3,31332,1,4,0)
 ;;=4^R47.01
 ;;^UTILITY(U,$J,358.3,31332,2)
 ;;=^5019488
 ;;^UTILITY(U,$J,358.3,31333,0)
 ;;=I69.920^^180^1952^2
 ;;^UTILITY(U,$J,358.3,31333,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31333,1,3,0)
 ;;=3^Aphasia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,31333,1,4,0)
 ;;=4^I69.920
 ;;^UTILITY(U,$J,358.3,31333,2)
 ;;=^5007553
 ;;^UTILITY(U,$J,358.3,31334,0)
 ;;=I69.91^^180^1952^3
 ;;^UTILITY(U,$J,358.3,31334,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31334,1,3,0)
 ;;=3^Cognitive deficits following unsp cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,31334,1,4,0)
 ;;=4^I69.91
 ;;^UTILITY(U,$J,358.3,31334,2)
 ;;=^5007552
 ;;^UTILITY(U,$J,358.3,31335,0)
 ;;=I69.991^^180^1952^5
 ;;^UTILITY(U,$J,358.3,31335,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31335,1,3,0)
 ;;=3^Dysphagia following unspecified cerebrovascular disease
 ;;^UTILITY(U,$J,358.3,31335,1,4,0)
 ;;=4^I69.991
 ;;^UTILITY(U,$J,358.3,31335,2)
 ;;=^5007569
 ;;^UTILITY(U,$J,358.3,31336,0)
 ;;=G11.1^^180^1952^6
 ;;^UTILITY(U,$J,358.3,31336,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31336,1,3,0)
 ;;=3^Early-onset cerebellar ataxia
 ;;^UTILITY(U,$J,358.3,31336,1,4,0)
 ;;=4^G11.1
 ;;^UTILITY(U,$J,358.3,31336,2)
 ;;=^5003753
 ;;^UTILITY(U,$J,358.3,31337,0)
 ;;=I69.952^^180^1952^11
 ;;^UTILITY(U,$J,358.3,31337,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31337,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left dominant side
 ;;^UTILITY(U,$J,358.3,31337,1,4,0)
 ;;=4^I69.952
 ;;^UTILITY(U,$J,358.3,31337,2)
 ;;=^5133586
 ;;^UTILITY(U,$J,358.3,31338,0)
 ;;=I69.954^^180^1952^12
 ;;^UTILITY(U,$J,358.3,31338,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31338,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff left nondom side
 ;;^UTILITY(U,$J,358.3,31338,1,4,0)
 ;;=4^I69.954
 ;;^UTILITY(U,$J,358.3,31338,2)
 ;;=^5133587
 ;;^UTILITY(U,$J,358.3,31339,0)
 ;;=I69.951^^180^1952^13
 ;;^UTILITY(U,$J,358.3,31339,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31339,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff right dominant side
 ;;^UTILITY(U,$J,358.3,31339,1,4,0)
 ;;=4^I69.951
 ;;^UTILITY(U,$J,358.3,31339,2)
 ;;=^5007561
 ;;^UTILITY(U,$J,358.3,31340,0)
 ;;=I69.953^^180^1952^14
 ;;^UTILITY(U,$J,358.3,31340,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31340,1,3,0)
 ;;=3^Hemiplga fol unsp cerebvasc disease aff right nondom side
 ;;^UTILITY(U,$J,358.3,31340,1,4,0)
 ;;=4^I69.953
 ;;^UTILITY(U,$J,358.3,31340,2)
 ;;=^5007562
 ;;^UTILITY(U,$J,358.3,31341,0)
 ;;=G81.92^^180^1952^7
 ;;^UTILITY(U,$J,358.3,31341,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31341,1,3,0)
 ;;=3^Hemiplegia, unspecified affecting left dominant side
 ;;^UTILITY(U,$J,358.3,31341,1,4,0)
 ;;=4^G81.92
 ;;^UTILITY(U,$J,358.3,31341,2)
 ;;=^5004122
 ;;^UTILITY(U,$J,358.3,31342,0)
 ;;=G81.94^^180^1952^8
 ;;^UTILITY(U,$J,358.3,31342,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,31342,1,3,0)
 ;;=3^Hemiplegia, unspecified affecting left nondominant side
 ;;^UTILITY(U,$J,358.3,31342,1,4,0)
 ;;=4^G81.94
 ;;
 ;;$END ROU IBDEI1RY
